David M A Mann

List of Publications by Year
in descending order

190 papers	37,635 citations	9786 73 h-index	3106 187 g-index
195 all docs	195 docs citations	195 times ranked	28034 citing authors

#	Article	IF	Citations
1	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
2	Association of missense and 5â€²-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393, 702-705.	27.8	3,333
3	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
4	TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications, 2006, 351, 602-611.	2.1	2,248
5	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
6	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006, 442, 916-919.	27.8	1,816
7	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
8	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica, 2007, 114, 5-22.	7.7	978
9	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	7.7	854
10	A harmonized classification system for FTLD-TDP pathology. Acta Neuropathologica, 2011, 122, 111-113.	7.7	817
11	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
12	Magnetite pollution nanoparticles in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10797-10801.	7.1	746
13	Prion-like spreading of pathological Î±-synuclein in brain. Brain, 2013, 136, 1128-1138.	7.6	691
14	Frontotemporal dementia. Lancet Neurology, The, 2005, 4, 771-780.	10.2	492
15	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain, 2012, 135, 693-708.	7.6	486
16	Disease-specific patterns of locus coeruleus cell loss. Annals of Neurology, 1992, 32, 667-676.	5.3	479
17	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	21.4	479
18	Prion-like Properties of Pathological TDP-43 Aggregates from Diseased Brains. Cell Reports, 2013, 4, 124-134.	6.4	418

#	Article	IF	Citations
19	Amyloid ? protein (A?) deposition: A?42(43) precedes A?40 in down Syndrome. Annals of Neurology, 1995, 37, 294-299.	5.3	378
20	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 2009, 117, 15-18.	7.7	377
21	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	9.0	374
22	ALZHEIMER'S PRESENILE DEMENTIA, SENILE DEMENTIA OF ALZHEIMER TYPE AND DOWN'S SYNDROME IN MIDDLE AGE FORM AN AGE RELATED CONTINUUM OF PATHOLOGICAL CHANGES. Neuropathology and Applied Neurobiology, 1984, 10, 185-207.	3.2	319
23	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
24	Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathologica, 2006, 112, 539-549.	7.7	298
25	Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathologica, 2007, 114, 31-38.	7.7	277
26	Progressive language disorder due to lobar atrophy. Annals of Neurology, 1992, 31, 174-183.	5.3	275
27	Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathologica, 2007, 113, 521-533.	7.7	274
28	Changes in the Monoamine Containing Neurones of the Human Cns in Senile Dementia. British Journal of Psychiatry, 1980, 136, 533-541.	2.8	273
29	Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. Brain, 2016, 139, 2957-2969.	7.6	220
30	Cognitive Phenotypes in Alzheimer's Disease and Genetic Risk. Cortex, 2007, 43, 835-845.	2.4	212
31	Presynaptic Serotonergic Dysfunction in Patients with Alzheimer's Disease. Journal of Neurochemistry, 1987, 48, 8-15.	3.9	211
32	The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain, 2011, 134, 2478-2492.	7.6	211
33	Amyloid Î² protein (AÎ²) deposition in chromosome 14â€“linked Alzheimer's disease: Predominance of AÎ²₄₂₍₄₃₎. Annals of Neurology, 1996, 40, 149-156.	5.3	208
34	Alzheimer's disease and Down's syndrome. Histopathology, 1988, 13, 125-137.	2.9	206
35	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
36	Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain, 2006, 129, 3091-3102.	7.6	185

#	Article	IF	Citations
37	Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathologica, 2009, 117, 55-62.	7.7	181
38	Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain, 2008, 131, 721-731.	7.6	178
39	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	2.9	178
40	Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathologica, 2016, 131, 267-280.	7.7	167
41	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathologica Communications, 2013, 1, 68.	5.2	162
42	LIPOPROTEIN PIGMENTSâ€"THEIR RELATIONSHIP TO AGEING IN THE HUMAN NERVOUS SYSTEM. Brain, 1974, 97, 481-488.	7.6	159
43	PATHOLOGICAL BASIS FOR NEUROTRANSMITTER CHANGES IN PARKINSON'S DISEASE. Neuropathology and Applied Neurobiology, 1983, 9, 3-19.	3.2	156
44	THE TOPOGRAPHY OF PLAQUES AND TANGLES IN DOWN'S SYNDROME PATIENTS OF DIFFERENT AGES. Neuropathology and Applied Neurobiology, 1986, 12, 447-457.	3.2	152
45	THE PROGRESSION OF THE PATHOLOGICAL CHANGES OF ALZHEIMER'S DISEASE IN FRONTAL AND TEMPORAL NEOCORTEX EXAMINED BOTH AT BIOPSY AND AT AUTOPSY. Neuropathology and Applied Neurobiology, 1988, 14, 177-195.	3.2	149
46	The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease. Acta Neuropathologica, 1990, 80, 318-327.	7.7	146
47	The Apolipoprotein E Îµ2 Allele and the Pathological Features in Cerebral Amyloid Angiopathy-related Hemorrhage. Journal of Neuropathology and Experimental Neurology, 1999, 58, 711-718.	1.7	142
48	TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimerâ€™s disease and frontotemporal lobar degeneration. Acta Neuropathologica, 2008, 116, 141-146.	7.7	142
49	Sporadic Pick's disease: A tauopathy characterized by a spectrum of pathological ? isoforms in gray and white matter. Annals of Neurology, 2002, 51, 730-739.	5.3	141
50	Early changes in extracellular matrix in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2017, 43, 167-182.	3.2	139
51	The selective vulnerability of nerve cells in Huntington's disease. Neuropathology and Applied Neurobiology, 2001, 27, 1-21.	3.2	135
52	Prevalence of amyloidâ€Î²2 pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
53	Pick's disease is associated with mutations in thetau gene. Annals of Neurology, 2000, 48, 859-867.	5.3	131
54	Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathologica, 2005, 110, 501-512.	7.7	131

#	Article	IF	Citations
55	TDP-43 pathological changes in early onset familial and sporadic Alzheimerâ€™s disease, late onset Alzheimerâ€™s disease and Downâ€™s Syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathologica, 2011, 122, 703-713.	7.7	128
56	Differential diagnosis of Alzheimerâ€™s disease using spectrochemical analysis of blood. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7929-E7938.	7.1	125
57	Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain, 2002, 125, 732-751.	7.6	116
58	Generation and characterization of novel conformation-specific monoclonal antibodies for Î±-synuclein pathology. Neurobiology of Disease, 2015, 79, 81-99.	4.4	116
59	Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathology, 2017, 27, 723-736.	4.1	112
60	The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathologica, 2011, 122, 99-110.	7.7	108
61	Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathologica, 2010, 120, 55-66.	7.7	97
62	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
63	Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain, 2012, 135, 3380-3391.	7.6	95
64	Apolipoprotein E Îµ2 allele promotes longevity and protects patients with DownÊ¼s syndrome from dementia. NeuroReport, 1994, 5, 2583-2585.	1.2	93
65	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathologica, 2006, 111, 329-340.	7.7	91
66	Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain, 2006, 129, 3124-3126.	7.6	91
67	Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 350-355.	1.9	91
68	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
69	THE QUANTITATIVE ASSESSMENT OF LIPOFUSCIN PIGMENT, CYTOPLASMIC RNA AND NUCLEOLAR VOLUME IN SENILE DEMENTIA. Neuropathology and Applied Neurobiology, 1978, 4, 129-135.	3.2	89
70	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathologica, 2012, 124, 373-382.	7.7	89
71	Frontotemporal dementia with Pickâ€type histology associated with Q336R mutation in the tau gene. Brain, 2004, 127, 1415-1426.	7.6	87
72	Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2009, 118, 647-658.	7.7	82

#	Article	IF	Citations
73	THE TOPOGRAPHIC DISTRIBUTION OF SENILE PLAQUES AND NEUROFIBRILLARY TANGLES IN THE BRAINS OF NON-DEMENTED PERSONS OF DIFFERENT AGES. Neuropathology and Applied Neurobiology, 1987, 13, 123-139.	3.2	81
74	Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathologica, 2006, 112, 551-559.	7.7	80
75	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	3.1	78
76	EARLY SENILE PLAQUES IN DOWN'S SYNDROME BRAINS SHOW A CLOSE RELATIONSHIP WITH CELL BODIES OF NEURONS. Neuropathology and Applied Neurobiology, 1989, 15, 531-542.	3.2	76
77	The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimerâ€™s disease in individuals with Down syndrome. Acta Neuropathologica Communications, 2018, 6, 56.	5.2	76
78	Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2004, 30, 46-56.	3.2	75
79	AN ANALYSIS OF THE MORPHOLOGY OF SENILE PLAQUES IN DOWN'S SYNDROME PATIENTS OF DIFFERENT AGES USING IMMUNOCYTOCHEMICAL AND LECTIN HISTOCHEMICAL TECHNIQUES. Neuropathology and Applied Neurobiology, 1989, 15, 317-329.	3.2	72
80	The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. Neuropathology and Applied Neurobiology, 2004, 30, 1-18.	3.2	72
81	Pathological correlates of frontotemporal lobar degeneration in the elderly. Acta Neuropathologica, 2011, 121, 365-371.	7.7	70
82	Patterns of microglial cell activation in frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2014, 40, 686-696.	3.2	70
83	The topographic distribution of brain atrophy in frontal lobe dementia. Acta Neuropathologica, 1993, 85, 334-40.	7.7	69
84	Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. Neurology, 2013, 80, 1881-1887.	1.1	67
85	A morphological analysis of senile plaques in the brains of nondemented persons of different ages using silver, immunocytochemical and lectin histochemical staining techniques. Neuropathology and Applied Neurobiology, 1990, 16, 17-25.	3.2	65
86	Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology, 2008, 196, 603-610.	3.1	62
87	Accumulation of dipeptide repeat proteins predates that of <scp>TDP</scp>â€43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in <scp>C9ORF72</scp> gene. Neuropathology and Applied Neurobiology, 2015, 41, 601-612.	3.2	62
88	Raman Spectroscopy to Diagnose Alzheimerâ€™s Disease and Dementia with Lewy Bodies in Blood. ACS Chemical Neuroscience, 2018, 9, 2786-2794.	3.5	62
89	Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimerâ€™s disease brain. Acta Neuropathologica Communications, 2013, 1, 54.	5.2	61
90	Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDPâ€43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathology and Applied Neurobiology, 2016, 42, 242-254.	3.2	61

#	Article	IF	Citations
91	Frontotemporal dementia with amyotrophic lateral sclerosis: A clinical comparison of patients with and without repeat expansions in C9orf72. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 172-176.	1.7	58
92	AN ULTRASTRUCTURAL ANALYSIS OF THE EFFECTS OF ACCUMULATION OF NEUROFIBRILLARY TANGLE IN PYRAMIDAL NEURONS OF THE CEREBRAL CORTEX IN ALZHEIMER'S DISEASE. Neuropathology and Applied Neurobiology, 1986, 12, 305-319.	3.2	55
93	Amyloid (A?) deposition in chromosome 1-linked Alzheimer's disease: The volga german families. Annals of Neurology, 1997, 41, 52-57.	5.3	54
94	NEUROFIBRILLARY PATHOLOGY AND PROTEIN SYNTHETIC CAPABILITY IN NERVE CELLS IN ALZHEIMER'S DISEASE. Neuropathology and Applied Neurobiology, 1981, 7, 37-47.	3.2	49
95	Microglial cells and amyloid ? protein (A?) deposition: association with A?40-plaques. Acta Neuropathologica, 1995, 90, 472-477.	7.7	48
96	Relationships in Alzheimer's disease between the extent of Abeta deposition in cerebral blood vessel walls, as cerebral amyloid angiopathy, and the amount of cerebrovascular smooth muscle cells and collagen. Neuropathology and Applied Neurobiology, 2006, 32, 332-340.	3.2	48
97	TDP-43 gene analysis in frontotemporal lobar degeneration. Neuroscience Letters, 2007, 419, 1-4.	2.1	47
98	Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance. Neurobiology of Aging, 2018, 63, 54-64.	3.1	47
99	Patterns and severity of vascular amyloid in Alzheimerâ€™s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 569-587.	7.7	47
100	Comparison of Common and Disease-Specific Post-translational Modifications of Pathological Tau Associated With a Wide Range of Tauopathies. Frontiers in Neuroscience, 2020, 14, 581936.	2.8	47
101	Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer's disease. Neuroscience Letters, 2003, 352, 137-140.	2.1	46
102	IMMUNOHISTOCHEMICAL STAINING OF SENILE PLAQUES. Neuropathology and Applied Neurobiology, 1982, 8, 55-61.	3.2	45
103	Co-Occurrence of Language and Behavioural Change in Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 205-213.	1.3	45
104	Deposition of amyloid ? protein in non-Alzheimer dementias: evidence for a neuronal origin of parenchymal deposits of ? protein in neurodegenerative disease. Acta Neuropathologica, 1992, 83, 415-419.	7.7	44
105	Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntingtonâ€™s disease. Brain Research, 2013, 1504, 16-24.	2.2	43
106	ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease. EBioMedicine, 2016, 9, 278-292.	6.1	40
107	Analysis of the hexanucleotide repeat in C9ORF72 in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1846.e5-1846.e6.	3.1	38
108	Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic Î²-amyloid pathology known as â€˜cotton woolâ€™ plaques. Neuropathology and Applied Neurobiology, 2001, 27, 189-196.	3.2	37

#	Article	IF	Citations
109	TREM2 analysis and increased risk of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 546.e9-546.e13.	3.1	37
110	Patterns of cerebral amyloid angiopathy define histopathological phenotypes in <scp>A</scp>lzheimer's disease. Neuropathology and Applied Neurobiology, 2014, 40, 136-148.	3.2	36
111	Symmetric dimethylation of poly-GR correlates with disease duration in C9orf72 FTLD and ALS and reduces poly-GR phase separation and toxicity. Acta Neuropathologica, 2020, 139, 407-410.	7.7	36
112	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. Neuropathology and Applied Neurobiology, 2006, 32, 374-387.	3.2	34
113	PATHOLOGICAL EVIDENCE FOR NEUROTRANSMITTER DEFICITS IN DOWN'S SYNDROME OF MIDDLE AGE. Journal of Intellectual Disability Research, 1985, 29, 125-135.	2.0	34
114	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. Neurobiology of Aging, 2009, 30, 656-665.	3.1	33
115	Amyloid or tau: the chicken or the egg?. Acta Neuropathologica, 2013, 126, 609-613.	7.7	33
116	Pathological tau deposition in Motor Neurone Disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathologica Communications, 2016, 4, 33.	5.2	33
117	DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders. Neurobiology of Disease, 2007, 28, 122-132.	4.4	32
118	Effect of topographical distribution of Î±-synuclein pathology on TDP-43 accumulation in Lewy body disease. Acta Neuropathologica, 2010, 120, 789-801.	7.7	31
119	Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 696-699.	1.9	30
120	TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. Acta Neuropathologica, 2009, 118, 359-369.	7.7	30
121	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. Neurobiology of Aging, 2018, 62, 244.e1-244.e8.	3.1	30
122	The DNA content of Purkinje cells in mammals. Journal of Comparative Neurology, 1978, 180, 345-347.	1.6	29
123	Atypical amyloid (AÎ²) deposition in the cerebellum in Alzheimer's disease: an immunohistochemical study using end-specific AÎ² monoclonal antibodies. Acta Neuropathologica, 1996, 91, 647-653.	7.7	29
124	Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease. Neuroscience Letters, 2005, 382, 221-226.	2.1	29
125	Plasma levels of progranulin and interleukin-6 in frontotemporal lobar degeneration. Neurobiology of Aging, 2015, 36, 1603.e1-1603.e4.	3.1	29
126	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29

#	Article	IF	Citations
127	Epitope mapping of antibodies against TDP-43 and detection of protease-resistant fragments of pathological TDP-43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Biochemical and Biophysical Research Communications, 2012, 417, 116-121.	2.1	27
128	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
129	Semantic dementia, progressive non-fluent aphasia and their association with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 711-712.	1.9	25
130	The nucleus basalis of Meynert in multi-infarct (vascular) dementia. Acta Neuropathologica, 1986, 71, 332-337.	7.7	24
131	Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. American Journal of Medical Genetics Part A, 2004, 125B, 79-82.	2.4	24
132	No interaction between tau and <scp>TDP</scp>â€43 pathologies in either frontotemporal lobar degeneration or motor neurone disease. Neuropathology and Applied Neurobiology, 2014, 40, 844-854.	3.2	23
133	Do NIAâ€AA criteria distinguish Alzheimer's disease from frontotemporal dementia?. Alzheimer's and Dementia, 2015, 11, 207-215.	0.8	23
134	Granulovacuolar degeneration in pyramidal cells of the hippocampus. Acta Neuropathologica, 1978, 42, 149-151.	7.7	22
135	Nuclear carrier and RNAâ€binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes. Neuropathology and Applied Neurobiology, 2013, 39, 157-165.	3.2	22
136	Pathological Correlates of Cognitive Impairment in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. Journal of Alzheimer's Disease, 2018, 64, 483-496.	2.6	22
137	Ultrastructural and biochemical classification of pathogenic tau, Î±-synuclein and TDP-43. Acta Neuropathologica, 2022, 143, 613-640.	7.7	22
138	A 3â€™-UTR polymorphism in the oxidized LDL receptor 1 gene increases AÎ²40 load as cerebral amyloid angiopathy in Alzheimerâ€™s disease. Acta Neuropathologica, 2006, 111, 15-20.	7.7	21
139	Autopsy proven sporadic frontotemporal dementia due to microvacuolar-type histology, with onset at 21 years of age. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1337-1339.	1.9	20
140	Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimerâ€™s disease pathology and is independent of tau, AÎ² and TDP-43 pathology. Acta Neuropathologica, 2011, 121, 635-649.	7.7	20
141	Heterogeneous ribonuclear protein A3 (hnRNP A3) is present in dipeptide repeat protein containing inclusions in Frontotemporal Lobar Degeneration and Motor Neurone disease associated with expansions in C9orf72 gene. Acta Neuropathologica Communications, 2017, 5, 31.	5.2	20
142	The role of lysosomes and autophagosomes in frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2019, 45, 244-261.	3.2	20
143	A small deletion in C9orf72 hides a proportion of expansion carriers in FTLD. Neurobiology of Aging, 2015, 36, 1601.e1-1601.e5.	3.1	19
144	A QUANTITATIVE STUDY OF THE ULTRASTRUCTURE OF PYRAMIDAL NEURONS OF THE CEREBRAL CORTEX IN ALZHEIMER'S DISEASE IN RELATIONSHIP TO THE DEGREE OF DEMENTIA. Neuropathology and Applied Neurobiology, 1986, 12, 321-329.	3.2	18

#	Article	IF	Citations
145	Extended post-mortem delay times should not be viewed as a deterrent to the scientific investigation of human brain tissue: a study from the Brains for Dementia Research Network Neuropathology Study Group, UK. Acta Neuropathologica, 2016, 132, 753-755.	7.7	18
146	Progressive Anomia Revisited: Focal Degeneration Associated with Progranulin Gene Mutation. Neurocase, 2008, 13, 366-377.	0.6	17
147	Human tauopathy-derived tau strains determine the substrates recruited for templated amplification. Brain, 2021, 144, 2333-2348.	7.6	17
148	NUCLEAR INCLUSIONS IN ALZHEIMER'S DISEASE. Neuropathology and Applied Neurobiology, 1980, 6, 245-253.	3.2	16
149	No association between polymorphisms in the lectin-like oxidised low density lipoprotein receptor (ORL1) gene on chromosome 12 and Alzheimerâ€™s disease in a UK cohort. Neuroscience Letters, 2004, 366, 126-129.	2.1	15
150	Heterogeneous ribonuclear protein E2 (hnRNP E2) is associated with TDP-43-immunoreactive neurites in Semantic Dementia but not with other TDP-43 pathological subtypes of Frontotemporal Lobar Degeneration. Acta Neuropathologica Communications, 2017, 5, 54.	5.2	15
151	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15
152	Patterns of glial cell activity in frontoâ€temporal dementia (lobar atrophy). Neuropathology and Applied Neurobiology, 1996, 22, 17-22.	3.2	14
153	What's in a name? Neuronal intermediate filament inclusion disease (NIFID), frontotemporal lobar degeneration-intermediate filament (FTLD-IF) or frontotemporal lobar degeneration-fused in sarcoma (FTLD-FUS)?. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1412-1414.	1.9	13
154	A UBQLN2 variant of unknown significance in frontotemporal lobar degeneration. Neurobiology of Aging, 2015, 36, 546.e15-546.e16.	3.1	13
155	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
156	Influence of APOE genotype in primary age-related tauopathy. Acta Neuropathologica Communications, 2020, 8, 215.	5.2	13
157	Synaptic changes in frontotemporal lobar degeneration: correlation with MAPT haplotype and APOE genotype. Neuropathology and Applied Neurobiology, 2011, 37, 366-380.	3.2	12
158	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
159	Pathological assessments for the presence of hexanucleotide repeat expansions in C9ORF72 in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2013, 1, 50.	5.2	11
160	C9ORF72in Dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1435-1436.	1.9	11
161	Histone deacetylases (<scp>HDACs</scp>) in frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2015, 41, 245-257.	3.2	11
162	p62/SQSTM1 analysis in frontotemporal lobar degeneration. Neurobiology of Aging, 2015, 36, 1603.e5-1603.e9.	3.1	11

#	Article	IF	Citations
163	A QUANTITATIVE STUDY OF THE GLIA OF THE PURKINJE CELL LAYER OF THE CEREBELLUM IN MAMMALS. Neuropathology and Applied Neurobiology, 1979, 5, 71-76.	3.2	10
164	Dipeptide repeat protein toxicity in frontotemporal lobar degeneration and in motor neurone disease associated with expansions in C9ORF72â€"a cautionary note. Neurobiology of Aging, 2015, 36, 1224-1226.	3.1	10
165	Immunohistochemical detection of C9orf72 protein in frontotemporal lobar degeneration and motor neurone disease: patterns of immunostaining and an evaluation of commercial antibodies. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 102-111.	1.7	10
166	Mid to lateâ€life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer's disease pathology at death. International Journal of Geriatric Psychiatry, 2021, 36, 713-721.	2.7	10
167	Scores Obtained from a Simple Cognitive Test of Visuospatial Episodic Memory Performed Decades before Death Are Associated with the Ultimate Presence of Alzheimer Disease Pathology. Dementia and Geriatric Cognitive Disorders, 2018, 45, 79-90.	1.5	9
168	Influence of APOE Genotype on Mortality and Cognitive Impairment. Journal of Alzheimer's Disease Reports, 2020, 4, 281-286.	2.2	8
169	Evaluation of ¹⁸F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in vivo in rodents and in human tissue. Theranostics, 2020, 10, 7938-7955.	10.0	7
170	Pick's disease is associated with mutations in the tau gene. Annals of Neurology, 2000, 48, 859-867.	5.3	7
171	Association between semantic dementia and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 115-117.	1.9	6
172	A Comparative Study of Pathological Outcomes in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age and Brains for Dementia Research Cohorts. Journal of Alzheimer's Disease, 2020, 73, 619-632.	2.6	6
173	Early changes in visuospatial episodic memory can help distinguish primary ageâ€related tauopathy from Alzheimerâ€™s disease. Neuropathology and Applied Neurobiology, 2021, 47, 1114-1116.	3.2	6
174	Lysosomes, autophagosomes and Alzheimer pathology in dementia with Lewy body disease. Neuropathology, 2018, 38, 347-360.	1.2	5
175	The Contribution of Vascular Pathology Toward Cognitive Impairment in Older Individuals with Intermediate Braak Stage Tau Pathology. Journal of Alzheimer's Disease, 2020, 77, 1005-1015.	2.6	5
176	Frontotemporal lobar degeneration in a very young patient is associated with fused in sarcoma (FUS) pathological changes. Neuropathology and Applied Neurobiology, 2012, 38, 101-104.	3.2	4
177	No association between head injury with loss of consciousness and Alzheimer disease pathologyâ€"Findings from the University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. International Journal of Geriatric Psychiatry, 2019, 34, 1262-1266.	2.7	4
178	Amyloid-PETâ€"Positive Patient With bvFTD. Neurology: Clinical Practice, 2021, 11, e952-e955.	1.6	4
179	Telephone Interview for Cognitive Status Scores Associate with Cognitive Impairment and Alzheimerâ€™s Disease Pathology at Death. Journal of Alzheimer's Disease, 2021, 84, 609-619.	2.6	4
180	Frontotemporal lobar degenerationâ€"a coming of age. Acta Neuropathologica, 2007, 114, 1-4.	7.7	3

#	Article	IF	Citations
181	The genetics and molecular pathology of frontotemporal lobar degeneration. , 2005, , 689-701.		3
182	The perforant pathway in Down's syndrome. Annals of Neurology, 1987, 21, 613-613.	5.3	2
183	Neuropathology of Alzheimer's disease: towards an understanding of the pathogenesis. Biochemical Society Transactions, 1989, 17, 73-75.	3.4	2
184	Reply: Atherosclerosis and vascular cognitive impairment neuropathological guideline. Brain, 2017, 140, e13-e13.	7.6	2
185	Microglial cells and amyloid ? protein (A?) deposition: association with A?40-containing plaques. Acta Neuropathologica, 1995, 90, 472-477.	7.7	2
186	TETRAPLOIDY AND BLINDNESS. Neuropathology and Applied Neurobiology, 1977, 3, 137-140.	3.2	1
187	C9ORF72: grabbing a tiger by the tail. Acta Neuropathologica, 2014, 127, 311-318.	7.7	1
188	The Neuropathology of Alzheimer's Disease. , 0, , 223-226.		0
189	The topographic distribution of brain atrophy in cortical Lewy body disease: comparison with Alzheimer's disease. Acta Neuropathologica, 1995, 89, 178-183.	7.7	0
190	The Role of Presenilins in Alzheimer's Disease. , 0, , 217-218.		0